Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Jabil Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Jabil Inc trades at $303.58 (market cap $31.35B). The key difference: Jabil Inc is far larger — about 2.5× Halozyme Therapeutics Inc. Common Stock's market cap, and Jabil Inc pays a 0.11% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Jabil Inc for 23 Days on average.
| HALO | JBL | |
|---|---|---|
Market Cap | $12.58B | $31.35B |
Volume | 2,179,278 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $115.22 | $385.50 |
52-Week Low | $61.63 | $192.49 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $14.49B | $33.63B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JBL trades at $301.76, up 0.76% today, with a bearish technical signal despite strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $29.80B in 2025 and a high ROE of 74.11%, though net margins are thin at 2.9%. AI infrastructure demand is driving optimistic fiscal 2027 guidance, with a consensus analyst price target of $434.75 implying significant upside.
The outlook is positive due to accelerating AI-led growth and strong analyst support, but risks include market volatility post-earnings and high valuation multiples. Investment appeal hinges on execution of projected 24% revenue growth, while current technical weakness may present a buying opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
